America’s National Kidney Foundation (NKF) has announced the launch of a new clinical trial using NIA innovation Dip.io.
The trial, using Dip.io’s smartphone app and urinalysis kit will provide important information on how to increase testing for chronic kidney disease (CKD) among patients with high blood pressure.
Hypertension, or high blood pressure, is a contributing risk factor to CKD. One of the best ways to test for CKD and assess kidney damage is a simple urine test which detects the presence of albumin. Dip.io enables lay users to conduct a urinalysis test at home and securely share results with their clinicians.
Approximately 30 million Americans have CKD, but nearly 90% do not know they have this condition. CKD progression can be slowed or halted if the disease, which often has no symptoms, is caught in its early stages.
“Early detection of CKD is crucial so that risk factors can be aggressively managed to prevent end-stage renal disease and cardiovascular disease,” said Alexander Chang, M.D., practicing nephrologist and assistant professor in the Kidney Health Research Institute at Geisinger.
Kerry Willis, Ph.D., Chief Scientific Officer, NKF, said: “Our hope is that a home-based test makes it easier for patients at risk for CKD to comply with regular albuminuria screening, and that this will lead to earlier diagnosis and treatment of CKD, reducing cardiovascular risk and preserving kidney function.
The new trial will:
- Examine the effect of mailed, Healthy.io smartphone urinalysis kits (Dip.io test) to improve albuminuria screening compliance and detection of albuminuria.
- Examine the feasibility of pharmacists in improving management of detected albuminuria, as pharmacists will be instructed to confirm test with urine albumin/creatinine ratio and treat albuminuria.
- Randomise 1,000 non-diabetic patients with hypertension who are receiving primary care at Geisinger. Patients will be randomized into two groups; one group receiving the usual care and one group who will receive a mailed Healthy.io urinalysis kit.
- A home test will be mailed to 500 Geisinger patients who have been diagnosed with hypertension but who do not have diabetes, along with instructions for downloading the smartphone app, to determine if the patient also has CKD.
- Geisinger patients will receive a letter and phone call educating them on the importance of screening for proteinuria from a team of nurses within the organization’s Care Gaps department. Appropriate follow-up will then be managed by the patient’s primary care provider and care team.
“Healthy.io is proud to pioneer its ‘adherence as a service’ platform with such forward-looking institutions as Geisinger and the National Kidney Foundation,” said Yonatan Adiri, CEO of Healthy.io.
“Our mission is to use advanced computer vision and patient centric design to let clinicians empower their patients at scale without additional cost or effort.”
He added: “Like a Netflix for adherence we lean on the spread of digital technology and efficient logistics to offer on demand testing delivered directly to the home. With a smartphone in your pocket, the point of care becomes wherever you are.”
The new clinical trial was announced NKF’s 2018 Annual Spring Clinical Meetings in Texas.
For more information visit www.healthy.io
